Healthcare Technology: A Capital Allocator's Framework

Healthcare technology is one of the most demanding categories I evaluate. The demographic tailwind is genuine, the operating problems are real, and the regulatory complexity creates moats that protect disciplined founders. But the same complexity that creates moats creates traps for investors who underweight category-specific risks. Here is the framework I use to separate the real opportunities from the traps.

Question one: who pays, and why

Healthcare is unique in that the buyer of the product is often not the user, and the user is often not the payer. A tool sold to a hospital is paid for by the hospital, used by clinicians, and ultimately funded by patients, payers, or government programs through whatever combination of mechanisms applies.

Before I evaluate any healthcare tech deal, I want a clear answer to "who writes the check, why do they write it, and what would change their mind." If the answer is vague or assumes a future shift in who pays, the deal is more risky than it appears.

Question two: the regulatory layer

Healthcare technology has at least one regulatory exposure that is not a question of if but of when. HIPAA. FDA, depending on the product. State-level licensing for clinical services. Stark Law and Anti-Kickback Statute exposure for payment-related products. The list is long, and each item has specific implications.

I want a clear-eyed answer about which regulations apply, what compliance looks like, and how the founder is funding the compliance work. A founder who hand-waves through this is signaling that the regulatory layer will surprise them later.

Question three: distribution

Healthcare distribution is hard. Selling to hospitals is slow. Selling to payers is slower. Selling to providers depends on a different sales motion than selling to consumers, and most early-stage healthcare tech founders underestimate how long the sales cycle will take.

I want to see a distribution strategy that matches the actual buyer, with realistic time-to-revenue assumptions. Plans that depend on six-month sales cycles into hospital systems are usually wrong by a factor of two or three.

Question four: clinical outcome substantiation

Healthcare buyers expect evidence. Whether they are hospitals, payers, or providers, they want to know that the product produces clinical outcomes that justify the cost and the workflow disruption.

Founders who have a clear pathway to clinical evidence (prospective study, retrospective analysis, peer-reviewed publication, or health economics outcomes research) are positioned to scale. Founders without one are betting that someone else will fund the evidence later.

What I look for in deals that work

The healthcare technology deals I have backed share three traits.

A clear payer thesis where the buyer's economic motivation is real and durable, not dependent on a future regulatory or reimbursement shift.

A regulatory approach that is funded as part of the business plan, not deferred until later.

A founding team that includes someone with direct healthcare operating experience. Pure software founders building into healthcare without a clinical or operations co-founder usually underperform the ones who have the inside view.

What I avoid

Founders who treat healthcare like another vertical SaaS category. The complexity is structural, not incidental.

Products whose value depends on a future shift in payer behavior, regulatory framework, or industry adoption pattern. Betting on industry change is much harder than betting on operator execution.

Tools whose primary differentiator is technology sophistication without a clear answer to who pays and why.

Why I keep investing here

Healthcare tech rewards patience. The deals that work produce returns over a longer timeline than typical B2B SaaS, but the durability of those businesses is genuinely high. The complexity that scares off undisciplined investors creates the moat for the disciplined ones.

The category rewards operators who do the work. It punishes investors who do not.